Sanofi betting on Lantus heir; EU OKs Boehringer cancer drug; Leo Burnett gets Pfizer biz;

Sanofi sign

@FiercePharma: Another Fresenius plant gets warning letter. This time in PR, on repeat labeling probs. Article from FiercePharmaManufacturing | Follow @FiercePharma

> Sanofi's ($SNY) Pierre Chancel, senior VP, global diabetes, says the drugmaker is expecting its improved version of Lantus to offset the biosimilar threat to the blockbuster. Story

> The FDA has strengthened the hepatitis B warning on GlaxoSmithKline's ($GSK) Arzerra and Roche's ($RHHBY) and Biogen Idec's ($BIIB) Rituxan. Report

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

> Boehringer Ingelheim has received EU approval for its targeted lung cancer drug Giotrif for specific patient populations. Story

> Bayer has been criticized by the U.K.'s Prescription Medicines Code of Practice Authority for paying for nightcaps for delegates at a conference in Amsterdam. Story

> A case against Japan's Takeda over the cancer risks of taking its diabetes drug Actos has gone to the jury in Baltimore, MD. Story

> Europe is at risk of a reintroduction of polio because of frequent travel between there and Israel, where the disease has been found in multiple samples of sewage. Story

Medical Device News

@FierceMedDev: EU committee backs tougher, U.S.-style device approval system. Article | Follow @FierceMedDev

@MarkHFierce: FierceDiagnostics has another great crop of stories. Check it out | Follow @MarkHFierce

@MichaelGFierce: Study: Artificial pancreas with inhaled insulin improves glucose control. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Olympus looks to the future with launch of sinus surgery tool. More

> Medtronic takes Insulet's settlement in insulin pump patent spat. Story

> Klobuchar, Hatch: Not so fast on device tax repeal. Article

> Roche, Pacific Biosciences seal $75M clinical Dx partnership. Item

Biotech News

@FierceBiotech: Eli Lilly will eventually have to come to grips with the fact that its R&D strategy and execution has been woeful. Story | Follow @FierceBiotech

@JohnCFierce: IPO 2013 revival update: 37 biotechs out, $2.8B raised from IPOs. More on the way. Feature | Follow @JohnCFierce

@DamianFierce: Merged at last on KKR's dime, PRA and RPS say they're the world's fourth-largest CRO. Article from FierceCRO | Follow @DamianFierce

@EmilyMFierce: $25M NIH project will set up genomic variants database for clinical use. More from FierceBiotech Research | Follow @EmilyMFierce

> Rise of personalized drugs means fewer 'dinosaur' trials. Item

> Merck KGaA amps up next-gen antibody pact with Ablynx. More

> Ipsen joins crowd in Cambridge with R&D move. Article

Pharma Manufacturing News

@EricPFierce: Kashmir-born Ph.D. picked by FDA to head office in India where problems mount. Story | Follow @EricPFierce

> Pfizer dumping plant, 140 workers in Australia. Item

> Sanofi building its largest African plant in Algeria. Report

> Purdue building $59M plant in North Carolina. More

> J&J says more Doxil shortages imminent, tied to Ben Venue problems. Story

> FDA warning points to infrastructure issue in India. Article

Vaccines News

> Merck KGaA lung cancer vaccine to re-enter Phase III. Item

> GSK, Merck and Pfizer join JP Morgan vaccine investment fund. Report

> European prices reapply old pressures to vaccine makers. Story

> Pandemic leads researchers to universal flu vaccine 'blueprint.' More

> U.K. gov makes U-turn on link between GSK vaccine and narcolepsy. Article

And Finally... Leo Burnett Vietnam has won Pfizer's ($PFE) advertising business in a competition with 5 other competitors, including Lowe and Ogilvy. Story

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.